COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.

Scott Guenthner; Wendy McFalda; Pearl Kwong; Kimberly Eads; Morgan McCafferty; Jayson Rieger; David K Glover; Cynthia Willson; Patrick Burnett; Melissa Olivadoti

doi:10.1007/S13555-021-00576-Y

COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.

Scott Guenthner
, Wendy McFalda
, Pearl Kwong
, Kimberly Eads
, Morgan McCafferty
, Jayson Rieger
, David K Glover
, Cynthia Willson
, Patrick Burnett
, Melissa Olivadoti

The Indiana Clinical Trials Center, Plainfield, IN, USA.
Clarkston Skin Research, Clarkston, MI, USA.
Solutions Through Advanced Research, Jacksonville, FL, USA.
Durham University
PBM Capital Group, Charlottesville, VA, USA.
Verrica Pharmaceuticals Inc, West Chester, PA, USA.
Verrica Pharmaceuticals Inc, West Chester, USA

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Dermatologic Therapy
DOIs	https://doi.org/10.1007/S13555-021-00576-Y
State	Published - Jul 21 2021
Externally published	Yes

Disciplines

Medicine and Health Sciences
Internal Medicine

Access to Document

10.1007/S13555-021-00576-YLicense: Unspecified

Cite this

Guenthner, S., McFalda, W., Kwong, P., Eads, K., McCafferty, M., Rieger, J., Glover, D. K., Willson, C., Burnett, P., & Olivadoti, M. (2021). COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. Dermatologic Therapy. https://doi.org/10.1007/S13555-021-00576-Y

COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts. / Guenthner, Scott; McFalda, Wendy; Kwong, Pearl et al.
In: Dermatologic Therapy, 21.07.2021.

Research output: Contribution to journal › Article › peer-review

Guenthner, S, McFalda, W, Kwong, P, Eads, K, McCafferty, M, Rieger, J, Glover, DK, Willson, C, Burnett, P & Olivadoti, M 2021, 'COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.', Dermatologic Therapy. https://doi.org/10.1007/S13555-021-00576-Y

@article{e1c8d3a0e0a547beb098bd09e4e362ad,

title = "COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7\% w/v) Under Occlusion for the Treatment of Common Warts.",

author = "Scott Guenthner and Wendy McFalda and Pearl Kwong and Kimberly Eads and Morgan McCafferty and Jayson Rieger and Glover, \{David K\} and Cynthia Willson and Patrick Burnett and Melissa Olivadoti",

note = "Introduction Verrucae vulgaris, or common warts, is a common skin condition for which there is no US Food and Drug Administration-approved treatment. Compounded cantharidin has been used to treat warts for years but lacks a controlled formulation, consistent application schedule and methods, and robust safety and efficacy studies.",

year = "2021",

month = jul,

day = "21",

doi = "10.1007/S13555-021-00576-Y",

language = "American English",

journal = "Dermatologic Therapy",

}

TY - JOUR

T1 - COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.

AU - Guenthner, Scott

AU - McFalda, Wendy

AU - Kwong, Pearl

AU - Eads, Kimberly

AU - McCafferty, Morgan

AU - Rieger, Jayson

AU - Glover, David K

AU - Willson, Cynthia

AU - Burnett, Patrick

AU - Olivadoti, Melissa

N1 - Introduction Verrucae vulgaris, or common warts, is a common skin condition for which there is no US Food and Drug Administration-approved treatment. Compounded cantharidin has been used to treat warts for years but lacks a controlled formulation, consistent application schedule and methods, and robust safety and efficacy studies.

PY - 2021/7/21

Y1 - 2021/7/21

UR - https://link.springer.com/article/10.1007/s13555-021-00576-y

U2 - 10.1007/S13555-021-00576-Y

DO - 10.1007/S13555-021-00576-Y

M3 - Article

JO - Dermatologic Therapy

JF - Dermatologic Therapy

ER -

COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.

Disciplines

Access to Document

Other files and links

Cite this